Gonsette R E, Defalque A, Demonty L
Belgian National Center for Multiple Sclerosis.
Riv Neurol. 1987 May-Jun;57(3):181-4.
Immune treatments have been used in multiple sclerosis (MS) since 20 years, but it is still difficult to estimate their clinical efficacy as well as their precise immunological effects. The development of the monoclonal antibodies techniques makes it possible to appreciate certain immune effects of these treatments in MS patients and to correlate them with clinical results. It appears that Cyclophosphamide is able to correct the CD4/CD8 ratio imbalance observed in most MS patients and that this correction is generally associated with a beneficial effect on the disease. Other immunosuppressive agents appear less effective both on the CD4/CD8 ratio and on the progression of MS.
二十年来,免疫疗法已被应用于治疗多发性硬化症(MS),但仍难以评估其临床疗效以及确切的免疫效应。单克隆抗体技术的发展使人们能够了解这些疗法在MS患者中的某些免疫效应,并将其与临床结果相关联。似乎环磷酰胺能够纠正大多数MS患者中观察到的CD4/CD8比例失衡,而且这种纠正通常与对疾病的有益作用相关。其他免疫抑制剂在CD4/CD8比例以及MS进展方面似乎效果较差。